|
|
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CARDIOVASCULAR
Department of Pharmacology (C.S., M.K., R.L.); Division of Hematology and Medical Oncology, Department of Medicine (M.J.B., A.J.M.), VA New York Harbor Health Care System; and Division of Hematology and Medical Oncology, Departments of Medicine (M.J.B., A.J.M.) and Pathology (A.J.M.), Weill Medical College of Cornell University, New York, New York
We recently reported that ATP, coreleased with norepinephrine (NE) from cardiac sympathetic nerves, increases NE exocytosis via a positive feedback mechanism. A neuronal ectonucleotidase (E-NTPDase) metabolizes the released ATP, decreasing NE exocytosis. Excessive NE release in myocardial ischemia exacerbates cardiac dysfunction. Thus, we studied whether the ATP-mediated autocrine amplification of NE release is operative in ischemia and, if so, whether it can be modulated by E-NTPDase and its recombinant equivalent, solCD39. Isolated, guinea pig hearts underwent 10- or 20-min ischemic episodes, wherein NE was released by exocytosis and reversal of the NE transporter, respectively. Furthermore, to restrict the role of E-NTPDase to transmitter ATP, sympathetic nerve endings were isolated (cardiac synaptosomes) and subjected to increasing periods of ischemia. Availability of released ATP at the nerve terminals was either increased via E-NTPDase inhibition or diminished by enhancing ATP hydrolysis with solCD39. P2X receptor blockade with PPADS was used to attenuate the effects of released ATP. We found that, in short-term ischemia (but, as anticipated, not in protracted ischemia, where NE release is carrier-mediated), ATP exocytosis was linearly correlated with that of NE. This indicates that by limiting the availability of ATP at sympathetic terminals, E-NTPDase effectively attenuates NE exocytosis in myocardial ischemia. Our findings suggest a key role for neuronal E-NTPDase in the control of adrenergic function in the ischemic heart. Because excessive NE release is an established cause of dysfunction in ischemic heart disease, solCD39 may offer a novel therapeutic approach to myocardial ischemia and its consequences.
Address correspondence to: Dr. Roberto Levi, Department of Pharmacology, Room LC419, 1300 York Ave., Weill Medical College of Cornell University, New York, NY 10021. E-mail: rlevi{at}med.cornell.edu
This article has been cited by other articles:
![]() |
U. Schaefer, T. Machida, M. J. Broekman, A. J. Marcus, and R. Levi Targeted Deletion of Ectonucleoside Triphosphate Diphosphohydrolase 1/CD39 Leads to Desensitization of Pre- and Postsynaptic Purinergic P2 Receptors J. Pharmacol. Exp. Ther., September 1, 2007; 322(3): 1269 - 1277. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Schaefer, S. Vorlova, T. Machida, J. P. Melchor, S. Strickland, and R. Levi Modulation of Sympathetic Activity by Tissue Plasminogen Activator Is Independent of Plasminogen and Urokinase J. Pharmacol. Exp. Ther., July 1, 2007; 322(1): 265 - 273. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Schaefer, T. Machida, S. Vorlova, S. Strickland, and R. Levi The plasminogen activator system modulates sympathetic nerve function J. Exp. Med., September 4, 2006; 203(9): 2191 - 2200. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Machida, P. M. Heerdt, A. C. Reid, U. Schafer, R. B. Silver, M. J. Broekman, A. J. Marcus, and R. Levi Ectonucleoside Triphosphate Diphosphohydrolase1/CD39, Localized in Neurons of Human and Porcine Heart, Modulates ATP-Induced Norepinephrine Exocytosis J. Pharmacol. Exp. Ther., May 1, 2005; 313(2): 570 - 577. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Burgdorf, A. Dendorfer, T. Kurz, E. Schomig, I. Stolting, F. Schutte, and G. Richardt Role of Neuronal KATP Channels and Extraneuronal Monoamine Transporter on Norepinephrine Overflow in a Model of Myocardial Low Flow Ischemia J. Pharmacol. Exp. Ther., April 1, 2004; 309(1): 42 - 48. [Abstract] [Full Text] |
||||
![]() |
J. B. Morris, T. M. Pham, B. Kenney, K. E. Sheppard, and E. A. Woodcock UTP Transactivates Epidermal Growth Factor Receptors and Promotes Cardiomyocyte Hypertrophy Despite Inhibiting Transcription of the Hypertrophic Marker Gene, Atrial Natriuretic Peptide J. Biol. Chem., March 5, 2004; 279(10): 8740 - 8746. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Queiroz, C. Talaia, and J. Goncalves ATP Modulates Noradrenaline Release by Activation of Inhibitory P2Y Receptors and Facilitatory P2X Receptors in the Rat Vas Deferens J. Pharmacol. Exp. Ther., November 1, 2003; 307(2): 809 - 815. [Abstract] [Full Text] [PDF] |
||||